Managing Osteoporosis in Chronic Kidney Disease
Author Information
Author(s): Muacevic Alexander, Adler John R, Tariq Fatima, Ahmad Mehjabeen, Subhan Muhammad, Zaid Alvi Syed Muhammad, Tariq Muhammad Umar, Ullah Sami, Khalid Asma, Bibi Ruqiya, Shafique Ur Rehman Muaz, Abbas Ayesha
Hypothesis
This study aims to evaluate the pathophysiology, diagnostic methods, and tailored management strategies for osteoporosis in CKD patients.
Conclusion
Osteoporosis management in CKD patients necessitates a personalized approach guided by the disease's stage and individual profile.
Supporting Evidence
- CKD-MBD is marked by alterations in calcium, phosphorus, parathyroid hormone, and vitamin D metabolism, significantly elevating fracture risk.
- Conventional treatments, such as bisphosphonates, denosumab, and teriparatide, demonstrate variable effectiveness in lowering fracture risk when tailored to CKD stages.
- Emerging pharmacologic agents hold promise in improving bone density, though evidence on these newer therapies remains limited.
Takeaway
People with kidney problems can also have weak bones, and doctors need to find the best way to help them stay strong and avoid fractures.
Methodology
A systematic literature search was conducted across multiple databases for studies published between 2017 and 2024, focusing on CKD-related osteoporosis.
Potential Biases
Data extraction and quality assessment were performed by multiple reviewers to reduce bias.
Limitations
The review may not fully capture the effectiveness of treatments in advanced CKD stages due to the exclusion of certain patient populations in studies.
Participant Demographics
The review includes studies involving CKD patients, particularly focusing on postmenopausal women.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website